Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, announce a definitive agreement for Lilly to acquire Verve. Verve is developing a pipeline of gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime. Under the terms of the agreement, Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share (an aggregate of up to approximately $1.3 billion).
Read the full article: Lilly to Acquire Verve Therapeutics to Advance One-Time Treatments for People with High Cardiovascular Risk //
Source: https://www.prnewswire.com/news-releases/lilly-to-acquire-verve-therapeutics-to-advance-one-time-treatments-for-people-with-high-cardiovascular-risk-302483684.html